Hemostat Uses

Rating: 5 - 1 review(s)
How long did you take this medication to work?

What is Hemostat?

Hemostat injection is used to control or prevent excessive or heavy bleeding during dental procedures in patients with hemophilia. Hemostat is for short-term use only, usually 2 to 8 days.

Hemostat injection is an antifibrinolytic agent. It works by blocking the breakdown of blood clots. It may also be used for other conditions as determined by your doctor.

Hemostat is available only with your doctor's prescription.

Hemostat indications

An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.

For short-term use (2-8 days) in haemophilia patients to reduce or prevent haemorrhage and to reduce the need for replacement therapy during and following tooth extraction.

For many haemostatic purposes including prevention of bleeding after surgery of trauma (eg, tonsillectomy and adenoidectomy, prostatic surgery, ocular trauma and cervical conisation), and to prevent rebleeding of subarachnoid haemorrhage, spontaneous bleeding in haemophilia and spontaneous or postoperative corneal oedema.

To treat primary or intrauterine device (IUD)-induced menorrhagia, gastric and intestinal haemorrhage, recurrent epistaxis and hereditary angioneurotic oedema. Hemostat also inhibits induced hyperfibrinolysis during thrombolytic treatment with plasminogen activators.

How should I use Hemostat?

Use Hemostat as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Ask your health care provider any questions you may have about how to use Hemostat.

Uses of Hemostat in details

There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.

Use: Labeled Indications

Menstrual bleeding, heavy (oral): Treatment of cyclic heavy menstrual bleeding.

Tooth extraction in patients with hemostatic defects (injection, oral [Hemostat; Canadian product]): Short-term use in hemophilia patients to reduce or prevent hemorrhage and reduce need for replacement therapy during and following tooth extraction.

Off Label Uses

Dental procedures in patients on oral anticoagulant therapy

Based on the American College of Chest Physicians guidelines for perioperative management of antithrombotic therapy, Hemostat is recommended to use, when needed, in combination with the continuation of oral anticoagulant therapy for the perioperative management of patients who require minor procedures.

Hemoptysis (nonmassive), treatment

Data from a small, single-center, prospective, randomized, double-blind, placebo-controlled trial suggest that nebulized Hemostat may be beneficial for the control of nonmassive hemoptysis by reducing the duration and volume of bleeding, with a low risk for side effects.

Hemostat description


Each capsule also contains sodium bisulfite, sodium lauryl sulfate and Yellow No.5 (Sunset Yellow FCF) as inactive ingredients. Each 5% w/v ampoule contains Tranexamic Acid 250 mg/5 mL, has a pH of 7-8 and an osmotic pressure ratio (with respect to physiological saline) of about 1.

Each 10% w/v ampoule contains Tranexamic Acid 250 mg/2.5 mL, has a pH of 7-8 and an osmotic pressure ratio (with respect to physiological saline) of about 2.

Hemostat is trans-4-aminomethylcyclohexanecarboxylic acid. It has a molecular formula of C8H15NO2, molecular weight of 157.21 and melting point of 386-390°C (decomposition). It occurs as white crystals or powder, odorless and has bitter taste. It is freely soluble in water or glacial acetic acid; very slightly soluble in ethanol; practically insoluble in ether; soluble in sodium hydroxide TS.

Capsule Size: No.2, total length of 17.6 mm and weight of about 350 mg.

Hemostat dosage

Hemostat Dosage

Generic name: Hemostat 100mg in 1mL

Dosage form: injection, solution

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Immediately before tooth extraction in patients with hemophilia, administer 10 mg per kg body weight of Hemostat intravenously together with replacement therapy. Following tooth extraction, intravenous therapy, at a dose of 10 mg per kg body weight three to four times daily, may be used for 2 to 8 days.

Note: For patients with moderate to severe impaired renal function, the following dosages are recommended:

Serum Creatinine (µmol/L) Hemostat

Intravenous Dosage

120 to 250 (1.36 to 2.83 mg/dL) 10 mg/kg twice daily
250 to 500 (2.83 to 5.66 mg/dL) 10 mg/kg daily
>500 (>5.66 mg/dL) 10 mg/kg every 48 hours


5 mg/kg every 24 hours

For intravenous infusion, Hemostat Injection may be mixed with most solutions for infusion such as electrolyte solutions, carbohydrate solutions, amino acid solutions, and Dextran solutions. Heparin may be added to Hemostat Injection. Hemostat Injection should NOT be mixed with blood. The drug is a synthetic amino acid, and should NOT be mixed with solutions containing penicillin.

Single-dose vials and ampules

Discard Hemostat vial or ampule and any remaining portion in the vial/ampule after single use.

The diluted mixture may be stored for up to 4 hours at room temperature prior to patient administration.

More about Hemostat (Hemostat)

Consumer resources

Professional resources

Related treatment guides

Hemostat interactions

See also:
What other drugs will affect Hemostat?


Contraindications for Co-Administration: Hemostat should not be co-adminstered with thrombin. Co-administration may cause a thrombosis tendency. It increases the tendency towards thrombosis due to the thrombogenic property of Hemostat.

Precautions for Co-Administration: Hemostat should be administered with care when co-administered with the following drugs.

Hemocoagulase: Co-administration at high doses may cause a thrombosis tendency. Due to the antiplasmin action of Hemostat, fibrin clots formed by hemocoagulase may persist in the blood stream for a relatively long period of time, which may result in a prolonged thrombotic state.

Batroxobin: Co-administration may cause thromboembolism. Hemostat inhibits the decomposition of desA fibrin polymer produced by batroxobin.

Coagulation Factor Agents (Eptacog-α): Coagulation may be further activated at sites with enhanced local fibrinolysis eg, the oral cavity. Coagulation factors exert hemostatic actions by activating the coagulation system, where as Hemostat exerts hemostatic actions by inhibiting the fibrinolytic system.

Hemostat side effects

See also:
What are the possible side effects of Hemostat?

Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Short-term Studies

The safety of Hemostat Tablets in the treatment of heavy menstrual bleeding (HMB) was studied in two randomized, double-blind, placebo-controlled studies. One study compared the effects of two doses of Hemostat Tablets (1950 mg and 3900 mg given daily for up to 5 days during each menstrual period) versus placebo over a 3-cycle treatment duration. A total of 304 women were randomized to this study, with 115 receiving at least one dose of 3900 mg/day of Hemostat Tablets. A second study compared the effects of Hemostat Tablets (3900 mg/day) versus placebo over a 6-cycle treatment duration. A total of 196 women were randomized to this study, with 117 receiving at least one dose of Hemostat Tablets. In both studies, subjects were generally healthy women who had menstrual blood loss of ≥ 80 mL.

In these studies, subjects were 18 to 49 years of age with a mean age of approximately 40 years, had cyclic menses every 21-35 days, and a BMI of approximately 32 kg/m2. On average, subjects had a history of HMB for approximately 10 years and 40% had fibroids as determined by transvaginal ultrasound. Approximately 70% were Caucasian, 25% were Black, and 5% were Asian, Native American, Pacific Islander, or Other. Seven percent (7%) of all subjects were of Hispanic origin. Women using hormonal contraception were excluded from the trials.

The rates of discontinuation due to adverse events during the two clinical trials were comparable between Hemostat Tablets and placebo. In the 3-cycle study, the rate in the 3900 mg Hemostat Tablets dose group was 0.8% as compared to 1.4% in the placebo group. In the 6-cycle study, the rate in the Hemostat Tablets group was 2.4% as compared to 4.1% in the placebo group. Across the studies, the combined exposure to 3900 mg/day Hemostat Tablets was 947 cycles and the average duration of use was 3.4 days per cycle.

A list of adverse events occurring in ≥ 5% of subjects and more frequently in Hemostat Tablets treated subjects receiving 3900 mg/day compared to placebo is provided in Table 2.

Long-term Studies

Long-term safety of Hemostat Tablets was studied in two open-label studies. In one study, subjects with physician-diagnosed heavy menstrual bleeding (not using the alkaline hematin methodology) were treated with 3900 mg/day for up to 5 days during each menstrual period for up to 27 menstrual cycles. A total of 781 subjects were enrolled and 239 completed the study through 27 menstrual cycles. A total of 12.4% of the subjects withdrew due to adverse events. Women using hormonal contraception were excluded from the study. The total exposure in this study to 3900 mg/day Hemostat Tablets was 10,213 cycles. The average duration of Hemostat Tablets use was 2.9 days per cycle.

A long-term open-label extension study of subjects from the two short-term efficacy studies was also conducted in which subjects were treated with 3900 mg/day for up to 5 days during each menstrual period of up to 9 menstrual cycles. A total of 288 subjects were enrolled and 19% subjects completed the study through 9 menstrual cycles. A total of 2.1% of the subjects withdrew due to adverse events. The total exposure to 3900 mg/day Hemostat Tablets in this study was 1,956 cycles. The average duration of Hemostat Tablets use was 3.5 days per cycle.

The types and severity of adverse events in these two long-term open-label trials were similar to those observed in the double-blind, placebo-controlled studies although the percentage of subjects reporting them was greater in the 27-month study, most likely because of the longer study duration.

A case of severe allergic reaction to Hemostat Tablets was reported in the extension trial, involving a subject on her fourth cycle of treatment, who experienced dyspnea, tightening of her throat, and facial flushing that required emergency medical treatment.

Postmarketing Experience

The following adverse reactions have been identified from postmarketing experience with Hemostat. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Based on US and worldwide postmarketing reports, the following have been reported in patients receiving Hemostat for various


Hemostat contraindications

See also:
What is the most important information I should know about Hemostat?

Thromboembolic Risk

​Do not prescribe Hemostat Tablets to women who are

Venous and arterial thrombosis or thromboembolism, as well as cases of retinal artery and retinal vein occlusions, have been reported with Hemostat.

Hypersensitivity to Hemostat

Do not prescribe Hemostat Tablets to women with known hypersensitivity to Hemostat.

Active ingredient matches for Hemostat:

Tranexamic Acid in Bangladesh.


Ethamsylate in India.

Unit description / dosage (Manufacturer)Price, USD
Hemostat 250mg TAB / 10$ 0.77
Hemostat 500mg TAB / 10$ 1.43
Hemostat 125mg INJ / 2ml$ 0.33
250 mg x 10's$ 0.77
500 mg x 10's$ 1.43
125 mg x 2ml$ 0.33
Hemostat 250 mg Tablet$ 0.08
Hemostat 500 mg Tablet$ 0.15
HEMOSTAT 125MG INJECTION 1 vial / 2 ML injection each (Meridian Medicare Ltd)$ 0.40
HEMOSTAT 250MG TABLET 1 strip / 10 tablets each (Meridian Medicare Ltd)$ 0.77
HEMOSTAT 500MG TABLET 1 strip / 10 tablets each (Meridian Enterprises Pvt Ltd)$ 1.59
HEMOSTAT tab 250 mg x 10's (Meridian)$ 0.77
HEMOSTAT tab 500 mg x 10's (Meridian)$ 1.43
HEMOSTAT inj 125 mg x 2ml (Meridian)$ 0.33
Hemostat cap 500 mg 2 x 10's (Aristopharma)
Hemostat cap 500 mg 3 x 10's (Aristopharma)
Hemostat cap 500 mg 5 x 10's (Aristopharma)
Hemostat inj 250 mg/5 mL 1's (Aristopharma)
Hemostat inj 250 mg/5 mL 10 x 1's (Aristopharma)
Hemostat inj 250 mg/5 mL 5 x 1's (Aristopharma)
Hemostat 125mg Injection (Meridian Medicare Ltd)$ 0.20
Hemostat 250mg Tablet (Meridian Medicare Ltd)$ 0.08
Hemostat 500mg Tablet (Meridian Enterprises Pvt Ltd)$ 0.16

List of Hemostat substitutes (brand and generic names):

Hemostan 500 mg/5 mL x 5's (Biomedis)$ 20.32
Hemostat Inj 250 mg Injection (Meridian Medicare Ltd.)$ 0.16
HEMOSTAT 2ML INJECTION 1 vial / 10 injections each (Meridian Enterprises Pvt Ltd)$ 0.32
HEMOSTIC 500MG INJECTION 1 vial / 2 ML injection each (Alembic Pharmaceuticals Ltd)$ 0.11
Hemostop 50 mg/1 mL x 10's (Navil Laboratories)
Hemostop 500 mg Tablet (Navil Laboratories)$ 0.14
Hemostop 250 mg Tablet (Navil Laboratories)$ 0.08
Hemotran 500 mg x 100's
Hemotran 500 mg/5 mL x 10 tube
Hemotrex 500 mg x 10's (Nutramedica)
Hemotrex 500 mg x 100's (Nutramedica)
Hemotrex cap 500 mg 10's (Nutramedica)
Hemotrex cap 500 mg 100's (Nutramedica)
Hemoxane 500 mg x 50's
Hemoxin cap 500 mg 100's (Drugmaker's Lab)
HEMOZEN 250MG TABLET 1 strip / 10 tablets each (Aglowmed Drugs Pvt. Ltd.)$ 0.80
Hemsamic cap 250 mg 2 x 10's (Tabros)
Hemsamic cap 500 mg 2 x 10's (Tabros)
Hemsamic inj 250 mg/5 mL 5's (Tabros)
Hemsamic inj 500 mg/5 mL 5's (Tabros)
HEMSTAT Capsule/ Tablet / 500mg / 10 units (Aglowmed Ltd)$ 1.19
HEMSTAT Capsule/ Tablet / 250mg / 10 units (Aglowmed Ltd)$ 0.63
Hemstat 250 mg Tablet (Aglowmed Ltd)$ 0.06
Hemstat 500 mg Tablet (Aglowmed Ltd)$ 0.12
HEMSTAT 250MG TABLET 1 strip / 10 tablets each (Aglowmed Ltd)$ 1.18
HEMSTAT 500MG TABLET 1 strip / 10 tablets each (Aglowmed Ltd)$ 1.22
Hemstat 250mg Tablet (Aglowmed Ltd)$ 0.12
Hemstat 500mg Tablet (Aglowmed Ltd)$ 0.12
Hemstate TX 500 mg Injection (Biosearch Organics (Ultramark Healthcare Pvt Ltd)$ 0.16
Hemstate TX 250+250 Tablet (Biosearch Organics (Ultramark Healthcare Pvt Ltd)$ 0.12
HEMSYL Capsule/ Tablet / 500mg / 10 units (Indoco Remedies Ltd)$ 1.56
HEMSYL Capsule/ Tablet / 250mg / 10 units (Indoco Remedies Ltd)$ 0.80
HEMSYL Injection / 250mg per 2ml / 2ml units (Indoco Remedies Ltd)$ 0.32
Hemsyl 250mg TAB / 10 (Indoco Remedies Ltd)$ 1.08
Hemsyl 500mg TAB / 10 (Indoco Remedies Ltd)$ 2.14
Hemsyl 125mg/mL AMP / 2mlx5 (Indoco Remedies Ltd)$ 1.94
250 mg x 10's (Indoco Remedies Ltd)$ 1.08
500 mg x 10's (Indoco Remedies Ltd)$ 2.14
125 mg x 1 mL x 2mlx5 (Indoco Remedies Ltd)$ 1.94
Hemsyl 250 mg Tablet (Indoco Remedies Ltd)$ 0.08
Hemsyl 500 mg Tablet (Indoco Remedies Ltd)$ 0.16
HEMSYL 125 MG INJECTION 1 vial / 2 ML injection each (Indoco Remedies Ltd)$ 0.55


  1. DailyMed. "TRANEXAMIC ACID: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. PubChem. "tranexamic acid". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  3. DrugBank. "tranexamic acid". http://www.drugbank.ca/drugs/DB00302 (accessed September 17, 2018).


The results of a survey conducted on ndrugs.com for Hemostat are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Hemostat. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

1 consumer reported useful

Was the Hemostat drug useful in terms of decreasing the symptom or the disease?
According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.

Consumer reported price estimates

No survey data has been collected yet

Consumer reported time for results

No survey data has been collected yet

4 consumers reported age


Consumer reviews

There are no reviews yet. Be the first to write one!

Your name: 
Spam protection:  < Type 27 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2022 ndrugs.com All Rights Reserved